LIGAND PHARMACEUTICALS INCORPORATED Revenue from Contract with Customer, Including Assessed Tax
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Revenue from Contract with Customer, Including Assessed Tax of $64.83 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2021-11-09
- LIGAND PHARMACEUTICALS INCORPORATED revenue from contract with customer, including assessed tax for the quarter ending 2021-09-30 was $64.83M, a 54.93% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED revenue from contract with customer, including assessed tax for the quarter ending 2021-06-30 was $84.67M, a 104.43% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED revenue from contract with customer, including assessed tax for the quarter ending 2021-03-31 was $55.15M, a 66.31% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED revenue from contract with customer, including assessed tax for the quarter ending 2020-09-30 was $41.85M, a 68.69% increase year-over-year.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month |
|---|---|---|---|
| 2021-09-30 | $64.83M 10-Q · filed 2021-11-09 | $149.51M derived: sum of 2 quarters · filed 2021-11-09 | $204.66M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $84.67M 10-Q · filed 2021-08-03 | $139.82M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $55.15M 10-Q · filed 2021-05-06 | ||
| 2020-09-30 | $41.85M 10-Q · filed 2021-11-09 | $83.27M derived: sum of 2 quarters · filed 2021-11-09 | $116.43M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $41.42M 10-Q · filed 2021-08-03 | $74.58M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $33.16M 10-Q · filed 2021-05-06 | ||
| 2019-09-30 | $24.81M 10-Q · filed 2020-11-06 | $49.80M derived: sum of 2 quarters · filed 2020-11-06 | $93.28M 10-Q · filed 2020-11-06 |
| 2019-06-30 | $24.99M 10-Q · filed 2020-08-07 | $68.47M 10-Q · filed 2020-08-07 | |
| 2019-03-31 | $43.48M 10-Q · filed 2020-05-08 | ||
| 2018-09-30 | $45.66M 10-Q · filed 2019-11-08 | $135.71M derived: sum of 2 quarters · filed 2019-11-08 | $191.86M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $90.04M 10-Q · filed 2019-08-08 | $146.20M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $56.16M 10-Q · filed 2019-05-09 | ||
| 2017-09-30 | $33.38M 10-Q · filed 2018-11-08 | $61.37M derived: sum of 2 quarters · filed 2018-11-08 | $90.64M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $28.00M 10-Q · filed 2018-08-08 | $57.26M 10-Q · filed 2018-08-08 |